ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
SRI International has been awarded two contracts by the National Cancer Institute to evaluate preclinical safety and pharmacology of potential cancer drugs and cancer prevention agents. Under one contract, funded at about $5 million from 2004 to 2009, SRI will test chemopreventative agents—drugs used in preventing the formation of cancer in at-risk populations rather than treating patients who already have the disease. The other contract, funded at about $7 million from 2004 to 2011, will focus on new cancer and chemotherapy drugs.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter